Synucleinopathies encompass a group of neurodegenerative disorders characterized by abnormal accumulation of alpha-synuclein protein aggregates in the brain. While commonly associated with Parkinson’s disease, recent research has implicated synucleinopathies in Alzheimer’s disease and other dementias. In Alzheimer’s, alpha-synuclein aggregates have been found to co-exist with tau and beta-amyloid plaques, hallmark proteins of Alzheimer's pathology. This co-occurrence suggests a potential overlap in disease mechanisms or synergistic pathological effects. The presence of alpha-synuclein pathology in Alzheimer’s patients often correlates with more severe cognitive impairment and faster disease progression. Understanding the role of synucleinopathies in Alzheimer’s and dementia could lead to novel diagnostic markers and therapeutic strategies targeting multiple pathological pathways, offering hope for more effective treatments in the future.
Title : Make a difference
Jacqueline Tuppen, Dementia UK, United Kingdom
Title : Imaging brain clearance in Alzheimer’s disease
Jun Hua, Johns Hopkins University , United States
Title : Association between APOE allele prevalence and Alzheimer's disease risk in Southwestern Uganda
Frank Balikoowa, African Research Center for Ageing & Dementia, Uganda
Title : Healthcare professionals in Somaliland had low levels of knowledge and attitudes towards dementia care: A pilot survey
Mohamed Abdilahi Duale, Frantz Fanon University, Somalia
Title : Association between depressive symptoms and cognitive impairment severity in a real-world memory clinic cohort
Yun Ju Hsieh, Taipei City Hospital, Taiwan
Title : Neuromodulation of scalp electroacupuncture in the treatment of autism spectrum disorder
Zhenhuan Liu, Nanhai Maternity and Children Hospital Affiliated to Guangzhou University of Chinese Medicine, China